Detalhe da pesquisa
1.
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 188(2): 369-377, 2021 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-34125340
2.
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Ann Hematol
; 98(5): 1217-1224, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30824956
3.
A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Br J Clin Pharmacol
; 84(10): 2336-2343, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29926514
4.
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.
Breast
; 58: 18-26, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33892316
5.
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
J Cancer Res Clin Oncol
; 144(6): 1087-1095, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-29671069
6.
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 16(3): 200-8, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25516338
7.
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
J Clin Oncol
; 31(34): 4349-57, 2013 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24145346
8.
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Clin Lung Cancer
; 10(4): 252-6, 2009 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-19632943